Genetic Clues to Predicting Evolocumab Response: Insights from YELLOW III Trial

 20% of patients did not respond well to the PCSK9 inhibitor evolocumab in the YELLOW III trial.

Patients with stable CAD who respond well to evolocumab show differences in gene expression compared to nonresponders.

Transcriptomics, or analysis of RNA transcripts, may help tailor medical therapies in the future.

YELLOW III previously demonstrated plaque morphology improvements when evolocumab was added to statins.

The current data suggest these changes result from suppressed inflammation, reduced oxidative stress, and improved mitochondrial function.

PCSK9 inhibitors are recommended in guidelines for patients with stable CAD not achieving sufficient LDL reduction with statins and ezetimibe.

In YELLOW III, 20% of patients had no improvements in their fibrous cap thickness or lipid core burden index despite reduced LDL levels.

Responders to evolocumab showed benefits in mitochondrial pathways that positively affected the fibrous cap and reduced plaque.

YELLOW III enrolled 137 CAD patients for 26 weeks of evolocumab on top of statin therapy.

Blood analysis revealed 571 downregulated transcripts involved in cell adhesion and communication.

It also identified 922 upregulated transcripts linked to mitochondrial function and protein synthesis.

80% of patients were classified as responders based on increased fibrous cap thickness.

Machine learning models were created using 38 genes for fibrous cap thickness and 71 genes for lipid core burden index.

Potential predictive genes are linked to IL-10 signaling, macrophage activation, and wound healing.

Future goals include developing biomarkers to determine therapy response before starting treatment.

YELLOW IV aims to validate these findings and explore mitochondrial metabolism strategies to limit atherosclerosis progression.

---

Take-Home Messages

1. Evolocumab's efficacy may depend on patient-specific genetic expression.
2. Transcriptomic analysis could personalize therapy in the future.
3. A significant 20% of patients may not benefit from PCSK9 inhibitors.
4. Machine learning models hold promise in predicting therapy response.
5. Future research should focus on biomarkers and enhancing mitochondrial metabolism.